Department of Special Care Center, Fuwai Hospital, National Clinical Research Center for Cardiovascular Diseases, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, No 167 Bei Li Shi Road, Xi Cheng District, Beijing, 100037, China.
Department of Cardiology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Clin Rheumatol. 2020 May;39(5):1591-1599. doi: 10.1007/s10067-019-04895-6. Epub 2020 Jan 3.
INTRODUCTION/OBJECTIVES: Fibroblast growth factor (FGF23) is an endocrine hormone that can be induced by inflammation and plays a role in the pathogenesis of cardiac abnormalities. Few studies have reported plasma FGF23 levels in patients with Takayasu arteritis (TAK). We hypothesized that the production of FGF23 in TAK is associated with abnormal cardiac mass.
Forty-seven patients diagnosed with TAK and 52 age- and gender-matched healthy controls were included in this observational study. Plasma FGF23 was detected by human enzyme-linked immunosorbent assay. Multivariable linear regression analyses were performed to examine the association between FGF23 and left ventricular mass index (LVMI).
Patients with TAK had higher plasma FGF23 than healthy controls [121.8 (84.5-168.8) vs. 86.7 (70.5-101.1) RU/ml, P < 0.001]. Patients with higher FGF23 concentrations were more likely to be females (100.0% vs. 75.0%, P = 0.01), angiographic type V (69.6% vs. 33.3%, P = 0.013), heart failure (43.5% vs. 12.5%, P = 0.018), and have higher LVMI [126.3 (81.1-177.7) vs. 85.9 (69.7-114.3) g/m, P = 0.041]. Plasma FGF23 was significantly associated with LVMI in TAK patients [β = 0.402, 95% confidence interval (CI) 0.032-0.301, P = 0.016], after adjusting for age, gender, disease duration, angiographic type (angiographic type V vs. non-angiographic type V), the presence of cardiovascular events and hypertension, and serum N-terminal pro-B-type natriuretic peptide in the multivariate linear regression. Age (β = - 0.399, P = 0.016) and the presence of angiographic type V (β = 0.376, P = 0.018) were identified to be significant determinants of plasma FGF23 in patients with TAK.
Plasma FGF23 was elevated in patients with TAK and was associated with LVMI. FGF23 may participate in the development of abnormal cardiac mass in patients with TAK.Key Points• Plasma FGF23 was elevated in patients with TAK.• FGF23 was significantly associated with LVMI in TAK.• Age and the presence of angiographic type V were determinants of plasma FGF23 in patients with TAK.
介绍/目的:成纤维细胞生长因子 23(FGF23)是一种内分泌激素,可被炎症诱导,在心脏异常发病机制中发挥作用。很少有研究报道过 Takayasu 动脉炎(TAK)患者的血浆 FGF23 水平。我们假设 TAK 中 FGF23 的产生与异常心脏质量有关。
本观察性研究纳入了 47 名确诊为 TAK 的患者和 52 名年龄和性别匹配的健康对照者。采用人酶联免疫吸附试验检测血浆 FGF23。进行多变量线性回归分析,以研究 FGF23 与左心室质量指数(LVMI)之间的关系。
与健康对照组相比,TAK 患者的血浆 FGF23 更高[121.8(84.5-168.8)比 86.7(70.5-101.1)RU/ml,P<0.001]。FGF23 浓度较高的患者更有可能为女性(100.0%比 75.0%,P=0.01)、血管造影类型 V(69.6%比 33.3%,P=0.013)、心力衰竭(43.5%比 12.5%,P=0.018),且 LVMI 更高[126.3(81.1-177.7)比 85.9(69.7-114.3)g/m,P=0.041]。TAK 患者的血浆 FGF23 与 LVMI 显著相关[β=0.402,95%置信区间(CI)0.032-0.301,P=0.016],在调整年龄、性别、疾病持续时间、血管造影类型(血管造影类型 V 比非血管造影类型 V)、心血管事件和高血压的存在以及血清 N 端脑钠肽前体后在多元线性回归中。年龄(β=-0.399,P=0.016)和血管造影类型 V 的存在(β=0.376,P=0.018)被确定为 TAK 患者血浆 FGF23 的重要决定因素。
TAK 患者的血浆 FGF23 升高,与 LVMI 相关。FGF23 可能参与 TAK 患者异常心肌质量的发展。
TAK 患者的血浆 FGF23 升高。
FGF23 与 TAK 中的 LVMI 显著相关。
年龄和血管造影类型 V 的存在是 TAK 患者血浆 FGF23 的决定因素。